Ionis Pharmaceuticals In Alliance With MD Anderson Cancer Center

Carlsbad-based pharmaceuticals developer Ionis Pharmaceuticals said this morning that it has tied with the University of Texas MD Anderson Cancer Center, in a strategic alliance. The strategic alliance focuses on the discovery and development of novel cancer therapeutics. The two said they are combining the antisense technology from Ionis with expertise at MD Anderson, to treat a variety of cancer in patients. Financial details of the alliance were not announced. The two said they will work together to validate novel cancer targets selected based on human genomic data. Ultimately, the two said they plan to identify a partner to complete development and to commercialize any drugs derived fro the effort.